Resources
Bridging the Global TB Diagnostic Gap: The Clinical Rigor Behind EMPE TBDx Scalable, Platform-Agnostic, and Rigorous: A New Standard for Molecular TB Screening
The World Health Organization (WHO), FIND, and the TB Alliance continuously stress a critical reality: expanding rapid, high-sensitivity testing is our ultimate weapon against the global tuberculosis epidemic. However, a major bottleneck persists. Centralized molecular platforms remain incredibly costly and demand heavy laboratory infrastructure, leaving laboratories and epidemiologists in desperate need of nimble, high-accuracy screening tools. To bridge this critical gap, EMPE Diagnostics developed EMPE TBDx—a three (3) gene target real-time PCR assay engineered specifically for the screening of active TB. Designed as an affordable option for lab-developed workflows, EMPE TBDx bypasses the typical pitfalls of unverified test components without compromising clinical integrity.Proving the Rigor: 726 Clinical Samples
The technology behind EMPE TBDx is backed by extensive clinical validation. In an in-house performance evaluation, the assay was tested using 726 clinical respiratory specimens across 14 separate runs.
When evaluated against traditional microbiological gold standards—such as MGIT culture and smear microscopy—the assay demonstrated:
- Outstanding Diagnostic Sensitivity: Approximately 87%
- High Robustness: Less than a 1% invalid result rate
Platform-Agnostic and Scalable
What truly sets this rapid TB detection test apart is its open, flexible design. It is completely platform-agnostic, meaning it seamlessly integrates into existing standard real-time thermal cyclers. Labs do not need to invest in expensive, proprietary hardware to achieve high-fidelity results.Key Performance Takeaway:
The kit provides reliable qualitative data from sputum and bronchoalveolar lavage (BAL) samples in under an hour.
As global surveillance demands high-fidelity, affordable tools, EMPE TBDx offers the scientific community an unmatched combination of commercial scalability and proven clinical rigor.